Clinical Trial

Rheological Functions of Erythrocyte in ESRD

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 11, 2025 (before its estimated March 20, 2025 completion). Its status may not reflect the trial's current state.
Summary
End-stage renal disease (ESRD) disrupts erythrocyte deformability due to osmotic imbalances, oxidative stress, and uremic toxins, leading to impaired microcirculation and oxygen transport. Dysregulation of ion channels, particularly the Gardos channel, exacerbates dehydration and eryptosis, further compromising vascular integrity. Given the critical role of erythrocyte flexibility in oxygen delivery, this study investigates its relationship with aerobic capacity in ESRD patients, highlighting potential mechanisms of microvascular dysfunction
Trial Details
NCT Number NCT06868888
Lead Sponsor Chang Gung Memorial Hospital
Conditions End-stage Renal Disease (ESRD)
Enrollment 40 participants
Start Date 2022-08-24
Primary Completion 2025-03-20 (estimated)
Study Completion 2025-03-26 (estimated)
Updated on ClinicalTrials.gov 2025-03-11